Hip AVN / ON (Avascular Necrosis – Osteonecrosis) Outcomes

hip avn osteonecrosis outcomes stem cells stem cell prp

Over this next few months we will be reviewing our large outcomes database and (now about 350 patients and almost 800 procedures) and reporting on the preliminary data in this blog as well as publishing multiple large case series.  Today the focus is on Hip Avascular Necrosis (AVN or osteonecrosis) patients and how they have fared.  This is a select group of 27 patients from a specific time period.  We measured the patient reported results in these patients who were all told they needed a hip replacement.  Instead of the hip replacement surgery, we injected their own mesenchymal stem cells into the bone via x-ray guidance, a procedure with much less downtime than even a surgical CORE decompression and certainly less invasive than a hip replacement surgery.  Of the 27 patients, 4 were lost to follow-up (couldn’t get outcome information), and 3 went on to hip replacements so their data was removed as any results might be due to the hip replacement.  All patients were between 3 months and more than a year out from their stem cell injection.  Of the 20 remaining patients, approximate mean reported improvement was 50%.  While we intend to clean up this data further and report this by disease severity (ARCO grade 1, 2, 3, 4+), I thought this was interesting information to report.

In the meantime, we continue to look at other types of patients such as knee osteoarthritis, hip OA, shoulder, rotator cuff, etc…  Again, this is preliminary data.

(Please note, these patients were treated with the Regenexx-C cultured stem cell procedure and not Regenexx-SD.  While Regenexx-SD does rely on the same stem cell type that was used to treat these patients and other clinics have reported good results using similar procedures that don’t rely on stem cell culturing, Regenexx-SD clinical effectiveness has not yet been established.)

Learn More About Regenexx^® Procedures

Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.

Your Email *

Include the weekly newsletter. It's free and you can unsubscribe at any time.

Submit

We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile